Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026)

Contineum Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 36.79% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $29.1 million, a 100.34% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, up 35.08% from the prior year.
• Non-Current Assets slipped to $8.4 million in Q1 2026 per CTNM's latest filing, from $8.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $8.7 million in Q4 2025 and bottomed at $891000.0 in Q3 2024.
• The 4-year median for Non-Current Assets is $6.0 million (2025), against an average of $5.0 million.
• Biggest YoY gain for Non-Current Assets was 564.42% in 2025; the steepest drop was 35.08% in 2025.
• Year by year, Non-Current Assets stood at $2.7 million in 2023, then jumped by 141.01% to $6.5 million in 2024, then surged by 35.08% to $8.7 million in 2025, then declined by 3.9% to $8.4 million in 2026.
• Per Business Quant, the three latest CTNM Non-Current Assets figures stand at $8.4 million (Q1 2026), $8.7 million (Q4 2025), and $5.9 million (Q3 2025).